A randomized, double-blind, placebo-controlled, phase 2 study to assess safety, tolerability and efficacy of RT001 in patients with amyotrophic lateral sclerosis.
Daphne N WeemeringMark MideiPeter MilnerVidhya GopalakrishnanAnil KumarAndrew J DannenbergTommy M BunteJuliette FoucherCaroline IngreViktorija ĶēniņaKarin RallmannLeonard H van den BergRuben P A van EijkPublished in: European journal of neurology (2023)
Initial data indicate that RT001 is safe and well-tolerated. Given the exploratory nature of the study, a larger clinical trial is required to evaluate its efficacy.